Dr. Samuel Golpanian | Facts & Fiction About Stem Cell Therapy
DR. SAMUEL GOLPANIAN, A LEADING MEDICAL EXPERT, AND ACTOR GEORGE HAMILTON, WHO HAS UNDERGONE EXPERIMENTAL TREATMENT, REPORT FROM THE FRONTLINES.
Stem cell therapy, one of the fastest growing medical trends, has been the subject of countless mainstream news reports circulating about how this promising health advancement has the potential to regenerate and repair damaged tissue, and possibly treat diseases and conditions for which few treatments currently exist.
On Tuesday, May 25 at 5:30 p.m., Altima is offering an exclusive opportunity to learn about this cutting-edge experimental therapy during a virtual forum and “telemed visit” with Dr. SAMUEL GOLPANIAN, Plastic & Reconstructive Surgeon, Temple University Hospital, Philadelphia, PA, and an expert on the state-of-the- science in stem cells for aging, longevity, heart disease, Alzheimer’s disease, and orthopedic uses.
Dr. Golpanian will be joined by American film and television actor and part-time Palm Beach resident, GEORGE HAMILTON, who will give insight about his personal experience.
During the forum, Dr. Golpanian will provide the latest data from LONGEVERON, NASDAQ (LGVN), a leading local (Miami-based) biotechnology company. He will separate fact from fiction, and answer questions from participants about this exciting new science, and help discern what is realistic and what is really being offered.
An industry leader and pioneer in this specialized field, LONGEVERON has been developing cellular therapies that specifically target age-related and life-threatening conditions, such as, Aging Frailty, Alzheimer’s disease, Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).
Longeveron is conducting US FDA Phase I and II clinical trials for its investigational product, LOMECEL-B™, which is derived from medicinal signaling cells (MSCs) sourced from bone marrow of young, healthy adult donors. In addition, Longeveron has received grants and funding from the National Institutes of Aging, the state of Maryland and the Alzheimer’s Association for its clinical trial programs.
With a mission to advance LOMOCEL-B, and other cell-based products/candidates into Phase 3 trials, the goal is to achieve regulatory approvals and broad use by the healthcare community. For more information visit www.longeveron.com.
To learn more about this exciting and cutting edge experimental therapy, and to receive an exclusive invitation to the virtual forum, please contact Maribel@AltimaPalmBeach.com.